Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Feb 6, 2016; 7(1): 133-138
Published online Feb 6, 2016. doi: 10.4292/wjgpt.v7.i1.133
Published online Feb 6, 2016. doi: 10.4292/wjgpt.v7.i1.133
Dendritic cell-based vaccine for pancreatic cancer in Japan
Masato Okamoto, Department of Advanced Immunotherapeutics, Kitasato University School of Pharmacy, Tokyo 108-8641, Japan
Masato Okamoto, Oncology Cencer, Kitasato Institute Hospital, Tokyo 108-8641, Japan
Masanori Kobayashi, Seren Clinic Nagoya, Nagoya, Aichi 460-0008, Japan
Yoshikazu Yonemitsu, R and D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan
Shigeo Koido, Division of Gastroenterology and Hepatology, Department of Internal Medicine, the Jikei University School of Medicine, Kashiwa, Chiba 277-8567, Japan
Sadamu Homma, Department of Oncology, the Jikei University School of Medicine, Tokyo 105-8461, Japan
Author contributions: Okamoto M designed the aim of the editorial, wrote the manuscript and generated the figure; Kobayashi M, Yonemitsu Y, Koido S and Homma S contributed to the writing of the manuscript.
Conflict-of-interest statement: Yonemitsu Y is a previous member of the Board of Directors on Science and Medicine at tella Inc; all remaining authors have declared no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Masato Okamoto, DDS, PhD, Professor, Department of Advanced Immunotherapeutics, Kitasato University School of Pharmacy, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan. okamotom@pharm.kitasato-u.ac.jp
Telephone: +81-3-57916495 Fax: +81-3-34469036
Received: July 7, 2015
Peer-review started: July 7, 2015
First decision: July 31, 2015
Revised: August 28, 2015
Accepted: November 13, 2015
Article in press: November 17, 2015
Published online: February 6, 2016
Processing time: 206 Days and 1.1 Hours
Peer-review started: July 7, 2015
First decision: July 31, 2015
Revised: August 28, 2015
Accepted: November 13, 2015
Article in press: November 17, 2015
Published online: February 6, 2016
Processing time: 206 Days and 1.1 Hours
Core Tip
Core tip: Dendritic cell (DC)-based cancer vaccine is expected as a strategy to augment the antigen-specific anti-cancer immune response. Vaccell, a DC vaccine which was optimized to fight against a cancer, has been developed in Japan. Here, we reviewed the development and clinical effects of the “Vaccell”. We conducted large-scale retrospective observations as well as prospective clinical trials, and obtained the findings strongly suggesting that there are “Responders” that the clinical benefits are provided by the DC vaccine. We are now planning a pivotal study of the Vaccell in Japan.